Alzamend Neuro Inc (ALZN)

$2.09 -0.08 (-3.69%)
Market Cap 8.17M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,260
Avg Vol 85,882
Day's Range N/A - N/A
Shares Out 3.80M
Stochastic %K 30%
Beta -0.25
Analysts Sell
Price Target $28.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
JDD808
JDD808 Feb. 2 at 12:21 AM
$ALZN positive news will send this
0 · Reply
Manwiththeplan
Manwiththeplan Jan. 30 at 8:12 PM
Bought $ALZN $CING $EVAX
0 · Reply
hiwatt
hiwatt Jan. 30 at 2:26 PM
$ALZN Would be nice to see institutional share percentage get above 5% when they finish reporting in the next 2 weeks. With 145,143 shares bought as apposed to just 6 sold in the last 6 months, that breaks down to a ratio of for every one share sold, 24190 get bought. You have to admit that's heading in the right direction.
0 · Reply
hiwatt
hiwatt Jan. 30 at 1:18 AM
$ALZN The new institutional numbers from last qt are starting to trickle in and ALZN is up 16% from 147k to 170k shares thanks to UBS group increasing their holdings from 2075 to 24567 shares.
0 · Reply
hiwatt
hiwatt Jan. 28 at 6:03 PM
$ALZN Below is a link to a podcast by Dr Nassir Ghaemi, professor of psychiatry at Tuft University, lecturer on psychiatry at Harvard Medical School, author of several books on mental illness as well as over 300 articles published in science publications, and is a featured psychiatric on CNN and Fox News. He is one of the most knowledgeable experts on lithium and he feels it should be prescribed more than it is. In his practice, he has over 50% of his patients on lithium. At minute 37.05 in the podcast, he is asked about AL001. https://www.youtube.com/live/KNRmWqusFRc?si=1L7ZyaZeIOpvjQ5X
1 · Reply
RadekPa
RadekPa Jan. 27 at 10:19 AM
$ALZN common
0 · Reply
hiwatt
hiwatt Jan. 27 at 12:20 AM
$ALZN https://www.youtube.com/watch?v=1YdRsBcAGNE
0 · Reply
hiwatt
hiwatt Jan. 26 at 6:39 PM
$ALZN Yea, it's call manipulation. Just like last week when we traded over 500K shares and it reach a new high for the year of $2.53. Two large trades went thru that day, one for over 140K and one for over 130k shares. The stock continued to creep up until the end of the day when someone started dumping some of those shares, They have been constantly dumping some of those shares since, triggering stop losses along the way back to $2.00 per share. When the selling hits a certain percentage, you see the buying begin once again on it's way to $3.00 on the "buy the rumor rally," IMO.
1 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 26 at 3:06 PM
$ALZN they are accepting all low bids. you know what that means.
0 · Reply
SvenneKaare
SvenneKaare Jan. 25 at 5:18 PM
$ALZN I fully expect news tomorrow or Tuesday!!🎉🚀🚀
0 · Reply
Latest News on ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Nov 19, 2025, 8:00 AM EST - 2 months ago

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 7, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 11 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 1 year ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Apr 4, 2023, 6:30 AM EDT - 3 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 11:59 PM EST - 4 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Dec 17, 2021, 9:54 AM EST - 4 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Aug 4, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 30, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 28, 2021, 3:07 PM EDT - 4 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 7:20 AM EDT - 4 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 11:23 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 1, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 17, 2021, 4:30 PM EDT - 5 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 16, 2021, 6:30 AM EDT - 5 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 5 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

JDD808
JDD808 Feb. 2 at 12:21 AM
$ALZN positive news will send this
0 · Reply
Manwiththeplan
Manwiththeplan Jan. 30 at 8:12 PM
Bought $ALZN $CING $EVAX
0 · Reply
hiwatt
hiwatt Jan. 30 at 2:26 PM
$ALZN Would be nice to see institutional share percentage get above 5% when they finish reporting in the next 2 weeks. With 145,143 shares bought as apposed to just 6 sold in the last 6 months, that breaks down to a ratio of for every one share sold, 24190 get bought. You have to admit that's heading in the right direction.
0 · Reply
hiwatt
hiwatt Jan. 30 at 1:18 AM
$ALZN The new institutional numbers from last qt are starting to trickle in and ALZN is up 16% from 147k to 170k shares thanks to UBS group increasing their holdings from 2075 to 24567 shares.
0 · Reply
hiwatt
hiwatt Jan. 28 at 6:03 PM
$ALZN Below is a link to a podcast by Dr Nassir Ghaemi, professor of psychiatry at Tuft University, lecturer on psychiatry at Harvard Medical School, author of several books on mental illness as well as over 300 articles published in science publications, and is a featured psychiatric on CNN and Fox News. He is one of the most knowledgeable experts on lithium and he feels it should be prescribed more than it is. In his practice, he has over 50% of his patients on lithium. At minute 37.05 in the podcast, he is asked about AL001. https://www.youtube.com/live/KNRmWqusFRc?si=1L7ZyaZeIOpvjQ5X
1 · Reply
RadekPa
RadekPa Jan. 27 at 10:19 AM
$ALZN common
0 · Reply
hiwatt
hiwatt Jan. 27 at 12:20 AM
$ALZN https://www.youtube.com/watch?v=1YdRsBcAGNE
0 · Reply
hiwatt
hiwatt Jan. 26 at 6:39 PM
$ALZN Yea, it's call manipulation. Just like last week when we traded over 500K shares and it reach a new high for the year of $2.53. Two large trades went thru that day, one for over 140K and one for over 130k shares. The stock continued to creep up until the end of the day when someone started dumping some of those shares, They have been constantly dumping some of those shares since, triggering stop losses along the way back to $2.00 per share. When the selling hits a certain percentage, you see the buying begin once again on it's way to $3.00 on the "buy the rumor rally," IMO.
1 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 26 at 3:06 PM
$ALZN they are accepting all low bids. you know what that means.
0 · Reply
SvenneKaare
SvenneKaare Jan. 25 at 5:18 PM
$ALZN I fully expect news tomorrow or Tuesday!!🎉🚀🚀
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 23 at 8:14 PM
$ALZN
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 23 at 6:15 PM
$ALZN codes being sent. a bunch of 4s traded. need to check my book on this. probably outdated what i have though lol
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Jan. 22 at 9:52 PM
$ALZN in or out. in or out. in or out.
0 · Reply
JackGalax
JackGalax Jan. 22 at 4:21 PM
$ALZN
0 · Reply
FriendOfmy
FriendOfmy Jan. 22 at 4:04 PM
$ALZN
0 · Reply
FriendOfmy
FriendOfmy Jan. 22 at 4:03 PM
$ALZN $5.00 run within two weeks. With good news of phase 2 easy $10 dollars run imo.
0 · Reply
H3D3RA
H3D3RA Jan. 22 at 3:30 PM
$ALZN
0 · Reply
L7_Trading
L7_Trading Jan. 21 at 9:12 PM
Looks like they are going to Halt-Up YGHJ in to Close... YHGJ is breaking out now.. Are they pumping up ticker YHGJ for 400% today!? Its insane what's going on in this crazy market.. Looks like all eyes are going to YHGJ now.. $JAGX $HCTI $ALZN $BBAI eoC
0 · Reply
Biotechtrdr
Biotechtrdr Jan. 20 at 5:41 PM
$ALZN we are only weeks away from a huge catalyst. i think the stock price should start climbing soon in anticipation of promising results. With good results this thing could pop several multiples, givin the very low float. All just in my opinion . Good luck to all!
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 1:58 PM
$ALZN RSI: 65.14, MACD: 0.0475 Vol: 0.18, MA20: 2.15, MA50: 2.19 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
hiwatt
hiwatt Jan. 17 at 4:14 PM
$ALZN Once again, highlighting 3 recent quotes from two Psychiatrist and one Psychiatry publication regarding AL001. 1--Dr Jim Phelps-- Of course, skeptics’ first response has been “these are mouse data.” Aron et al point out that lithium levels in human and mouse brains are COMPARABLE, supporting the relevance of mouse models for studying the biological effects of lithium. A novel form of lithium (Al001) shows "better brain absorption." in mice is in phase 2 in humans trials with millions in funding, but nonprofit funding will be needed for lithium orotate. 2--Dr Garrett Rossi-- We may be witnessing the next evolution (AL001)in one of psychiatry's most effective treatments and it's coming soon. 3--Carlat Publishing--It will take years to figure out appropriate serum levels for lithium orotate, and by then a new lithium salt (Al001) may have stolen orotate's aura.
0 · Reply
hiwatt
hiwatt Jan. 15 at 11:45 PM
$ALZN https://youtube.com/shorts/vwtl5kdRWzM?si=slSDc5iKHdj5Qww3
0 · Reply